콘텐츠로 건너뛰기
Merck
  • Investigations into the Role of Metabolism in the Inflammatory Response of BV2 Microglial Cells.

Investigations into the Role of Metabolism in the Inflammatory Response of BV2 Microglial Cells.

Antioxidants (Basel, Switzerland) (2021-01-21)
Pamela Maher
초록

Although the hallmarks of Alzheimer's disease (AD) are amyloid beta plaques and neurofibrillary tangles, there is growing evidence that neuroinflammation, mitochondrial dysfunction and oxidative stress play important roles in disease development and progression. A major risk factor for the development of AD is diabetes, which is also characterized by oxidative stress and mitochondrial dysfunction along with chronic, low-grade inflammation. Increasing evidence indicates that in immune cells, the induction of a pro-inflammatory phenotype is associated with a shift from oxidative phosphorylation (OXPHOS) to glycolysis. However, whether hyperglycemia also contributes to this shift is not clear. Several different approaches including culturing BV2 microglial cells in different carbon sources, using enzyme inhibitors and knocking down key pathway elements were used in conjunction with bacterial lipopolysaccharide (LPS) activation to address this question. The results indicate that while high glucose favors NO production, pro-inflammatory cytokine production is highest in the presence of carbon sources that drive OXPHOS. In addition, among the carbon sources that drive OXPHOS, glutamine is a very potent inducer of IL6 production. This effect is dampened in the presence of glucose. Together, these results may provide new prospects for the therapeutic manipulation of neuroinflammation in the context of diabetes and AD.

MATERIALS
제품 번호
브랜드
제품 설명

Sigma-Aldrich
Carbonyl cyanide 4-(trifluoromethoxy)phenylhydrazone, ≥98% (TLC), powder
Sigma-Aldrich
Myxothiazol, from Myxococcus fulvus Mx f85, ≥98% (HPLC)
Sigma-Aldrich
Thallium(III) trifluoroacetate, technical grade
Sigma-Aldrich
Indole-3-acetic acid sodium salt, BioReagent, suitable for plant cell culture, ≥98%
Sigma-Aldrich
MISSION® esiRNA, targeting human ATPIF1